» Articles » PMID: 27667133

Hepatitis E Virus RNA in Australian Blood Donations

Overview
Journal Transfusion
Specialty Hematology
Date 2016 Sep 27
PMID 27667133
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Hepatitis E virus (HEV) poses a risk to transfusion safety. In Australia, locally acquired HEV is rare and cases are mainly reported in travelers returning from countries endemic for HEV. The risk posed by HEV to transfusion safety in Australia is unknown; therefore, we aimed to measure the rate of current HEV infection in Australian blood donations.

Study Design And Methods: A total of 14,799 blood donations were tested for HEV RNA by transcription-mediated amplification, with confirmatory testing by reverse transcription-polymerase chain reaction. Viral load quantification and phylogenetic analysis was performed on HEV RNA-positive samples.

Results: One (0.0068%; 95% confidence interval [CI], 0.0002%-0.0376%) sample was confirmed positive for HEV RNA, resulting in a risk of collecting a HEV-viremic donation of 1 in 14,799 (95% CI, 1 in 584,530 to 1 in 2,657). The viral load in this sample was approximately 15,000 IU/mL, and it was determined to be Genotype 3.

Discussion: Our finding of 1 in 14,799 Australian donations positive for HEV RNA is lower than that from many other developed countries; this is consistent with the relatively low seroprevalence in Australia. As this HEV RNA-positive sample was Genotype 3, it seems likely that this infection was acquired through zoonotic transmission, either within Australia or overseas in a developed nation. HEV has the potential to pose a risk to transfusion safety in Australia; however, additional, larger studies are required to quantify the magnitude of this risk.

Citing Articles

Assessment of Hepatitis E virus transmission risks: a comprehensive review of cases among blood transfusion recipients and blood donors.

Singson S, Shastry S, Sudheesh N, Chawla K, Madiyal M, Kandasamy D Infect Ecol Epidemiol. 2024; 14(1):2406834.

PMID: 39421644 PMC: 11486055. DOI: 10.1080/20008686.2024.2406834.


Higher Risk of HEV Transmission and Exposure among Blood Donors in Europe and Asia in Comparison to North America: A Meta-Analysis.

Wolski A, Pischke S, Ozga A, Addo M, Horvatits T Pathogens. 2023; 12(3).

PMID: 36986347 PMC: 10059948. DOI: 10.3390/pathogens12030425.


Transfusion-transmitted hepatitis E: What we know so far?.

Cheung C, Wong S, Law A, Law M World J Gastroenterol. 2022; 28(1):47-75.

PMID: 35125819 PMC: 8793017. DOI: 10.3748/wjg.v28.i1.47.


Development and Optimization of an Enzyme Immunoassay to Detect Serum Antibodies against the Hepatitis E Virus in Pigs, Using Plant-Derived ORF2 Recombinant Protein.

Takova K, Koynarski T, Minkov G, Toneva V, Mardanova E, Ravin N Vaccines (Basel). 2021; 9(9).

PMID: 34579228 PMC: 8473109. DOI: 10.3390/vaccines9090991.


Prevalence of Hepatitis E Virus Infection Among Blood Donors in the Eastern Province of Saudi Arabia.

Al Dossary R, Alnafie A, Aljaroodi S, Rahman J, Hunasemarada B, Alkharsah K J Multidiscip Healthc. 2021; 14:2381-2390.

PMID: 34475765 PMC: 8407670. DOI: 10.2147/JMDH.S328029.